A multicentre phase I/II study of TAS-102 with nintedanib in patients with metastatic colorectal cancer refractory to standard therapies (N-TASK FORCE: EPOC1410); Phase I results
2016
Keywords:
-
Correction
-
Source
-
Cite
-
Save
0
References
2
Citations
NaN
KQI